McKesson (MCK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on November 6, 2024, might help the stock move higher if these key numbers are better than ...

McKesson (MCK) closed the most recent trading day at $508.95, moving +0.3% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.27%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq appreciated by 0.26%.The the stock of prescription drug distributor has risen by 3.92% in the past month, leading the Medical sector's loss of 4.14% and the S&P 500's gain of 2%.Investors will be eagerly watching for the performance of McKesson in its upcomi ...

The latest trading session saw McKesson (MCK) ending at $513.67, denoting a +0.86% adjustment from its last day's close. The stock's change was more than the S&P 500's daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.The prescription drug distributor's stock has dropped by 2.03% in the past month, exceeding the Medical sector's loss of 3.35% and lagging the S&P 500's gain of 4.31%.Investors will be eagerly watching for the performance of McKesson in its upcoming ear ...

I'm a value investor who enjoys using classical value ratios to pick my portfolio. Long-term focused on low P/B, P/FCF, Owner Earnings discounting, PEG ratios, the Graham Number and an occasional net-net hunter. I also believe tracking earnings growth versus price appreciation is an essential element to any quality evaluation.I advocate self-indexing primarily using the Dow Jones Industrial Average as my index of choice combined with Joel Greenblatt's Magic Formula. This can help with tax efficiency owning ...

McKesson (MCK) closed at $488.78 in the latest trading session, marking a -1.95% move from the prior day. This change lagged the S&P 500's daily gain of 0.01%. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. The prescription drug distributor's shares have seen a decrease of 13.15% over the last month, not keeping up with the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21%. The investment community will be paying close attention to the earnings perf ...

In the latest trading session, McKesson (MCK) closed at $479.06, marking a -0.02% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0.62%, while the tech-heavy Nasdaq added 0.6%.Prior to today's trading, shares of the prescription drug distributor had lost 13.93% over the past month. This has lagged the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71% in that time.Analysts and investors alike will be keeping a close eye o ...

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this prescription drug distributor have returned -13.9%, compared to the Zacks S&P 500 composite's +1.7% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has lost 2.8%. The key question now is: What could be the stock's future direction?While m ...

The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally. After a rapid move lower, shares of McKesson Corporation MCKhave become oversold. They have also reached a price level that may provide support. This is why our team of trading experts has made it our Stock of the Day. The red line on the chart below is called a Bollinger Band. It is two standard deviations below the 20-day moving average. According to statistics and ...

McKesson Corporation (MCK) is well-poised for growth in the coming quarters, courtesy of its strong Biologics business. The optimism led by a decent first-quarter fiscal 2025 performance and improving demand for healthcare are expected to contribute further. However, stiff competition and weaker generic pharmaceutical pricing trends persist.In the past one year, MCK shares have gained 36.1% compared with the industry’s rise of 3.5%. The S&P 500 has gained 27.1% in the same time frame.The renowned healthcare ...

BCFC Introduction This is a very special article, as I discuss a company I have never covered before. As I have been on Seeking Alpha for almost a decade, that doesn't happen very often. As some readers may know, I check the S&P 500's worst performers every day. I do this for the same reason I always check the clearance shelf in stores. You never know when you'll find a bargain! Earlier this month, the McKesson Corporation (NYSE:MCK) stood out, as it saw its stock price decline from $580 to almost $500. ...